Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

Rhea-AI Summary

Metagenomi (Nasdaq: MGX) will present new preclinical data supporting APOC3 as the third collaboration target with Ionis Pharmaceuticals at the Nature Conference “Cracking the Code: Nucleic Acid Medicines Coming of Age” on Dec 8-10, 2025 in Boston.

Presentation title: CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia. Presenter: Alan Brooks, PhD, Senior Vice President of Research at Metagenomi. Date/time: Monday, December 8, 2025 at 2:45 p.m. EST. The talk covers preclinical evidence supporting the APOC3 target in the Ionis collaboration.

EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at the Nature Conference “Cracking the Code: Nucleic Acid Medicines Coming of Age” taking place December 8-10, 2025, in Boston, MA.

Nature Conference “Cracking the Code: Nucleic Acid Medicines Coming of Age”

Title: CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia

Presenters: Alan Brooks, PhD, Senior Vice President of Research at Metagenomi

Date/time: Monday, December 8, 2025, at 2:45 p.m. EST

About Metagenomi

Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, integration and correction.

MGX-001, the Company’s lead, wholly-owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with best-in-class treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. The Company is also currently pursuing other secreted protein deficiencies leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co.

Cautionary Note Regarding Forward-Looking Statements
This press release contains ​“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as ​ “anticipate,” ​ “believe,” ​ “could,” “estimate,” ​“expect,” ​“goal,” ​“intend,” ​“look forward to,” ​“may,” ​“plan,” ​“potential,” ​“predict,” ​“project,” ​“should,” ​“will,” ​“would” and similar expressions include, but are not limited to, any statements relating to our product development programs, including the timing of and our ability to conduct IND-enabling studies and make regulatory filings such as INDs, expectations regarding MGX-001, including the preclinical profile being potentially competitive with best-in-class treatment options and timing to submit the IND/CTA package, statements regarding the Company’s plans to prioritize its preclinical pipeline and potential for value creation and sustainable growth, statements regarding upcoming milestones including the nomination of development candidates, statements concerning the potential of therapies and product candidates, statements concerning the impact of the organizational restructuring, statements concerning our anticipated cash runway, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of IND submissions and starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation and the current regulatory environment; patent and intellectual property matters; competition; the volatility of capital markets and other adverse macroeconomic factors; as well as other risks described in ​“Risk Factors,” in our most recent Form 10-K and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Investor Contacts:

Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com

or

Kiki Patel, PharmD
Gilmartin Group
kiki@gilmartinir.com

FAQ

What will Metagenomi (MGX) present about APOC3 at the Nature Conference on December 8, 2025?

Metagenomi will present preclinical data titled “CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia.”

When and where is Metagenomi's MGX presentation on APOC3 scheduled during the Nature Conference?

The presentation is scheduled for Monday, December 8, 2025 at 2:45 p.m. EST in Boston during the Dec 8–10 conference.

Who is presenting Metagenomi's MGX APOC3 data at the Dec 2025 Nature Conference?

Alan Brooks, PhD, Senior Vice President of Research at Metagenomi, is listed as the presenter.

What is the focus of Metagenomi and Ionis's collaboration referenced in the MGX announcement?

The collaboration includes APOC3 as the third target, with the presentation covering preclinical evidence supporting that target.

How does Metagenomi describe the potential therapy for APOC3 at the conference?

The presentation frames APOC3 knockout as a one-time CRISPR/Cas treatment approach for severe hypertriglyceridemia based on preclinical data.

Will Metagenomi (MGX) present other collaboration details with Ionis at the Nature Conference?

The announcement specifies preclinical data supporting the APOC3 target in the collaboration but does not list additional collaboration terms.